Dianthus Therapeutics Inc. (DNTH)
NASDAQ: DNTHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DNTH stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.76B
- EPS (TTM)
- -$4.08
- Dividend yield
- None
- 52-week range
- 35.84 – 117.88
- Day range
- 82.58 – 85.67
- Volume / Avg
- 784.84K / 848.96K
- Beta
- —
- Shares outstanding
- 56.31M
52-week range
DNTH stock today
Shares of Dianthus Therapeutics (DNTH) finished lower on Nov 20 at $84.55, a drop of 0.33% or $0.28 per share, versus the S&P 500's 3.70% decline. At this level, DNTH sits in the middle of its 52-week range of $35.84 to $117.88: 28.3% below the high, set on Aug 19, 2026 and 135.9% above the low. DNTH is up 105.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 104.0%.
Dianthus Therapeutics has posted a net loss over the last twelve months (EPS of -$4.08), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Dianthus Therapeutics
Company profileDianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Marino Garcia M.B.A.
- Headquarters
- New York, NY
- Employees
- 92
- IPO year
- 2018
- Website
- dianthustx.com
Financial highlights
Full financialsIn fiscal 2025, Dianthus Therapeutics generated $2.0 million in revenue, down 67.3% from fiscal 2024, the first decline in the 10 years shown. Dianthus Therapeutics reported a net loss of $162.3 million, compared with a loss of $85.0 million a year earlier. Operating margin was -8739.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.04M | $6.24M | $2.83M | — | — |
| Growth | -67.35% | +120.63% | — | — | — |
| Net income | $-162.34M | $-84.97M | $-43.55M | $-28.48M | $-71.14M |
| EPS (diluted) | $-4.20 | $-2.55 | $-8.45 | $-32.57 | $-1.29 |
Analyst forecast
ForecastConsensus (18 analysts)
strong_buy
Avg. price target
$139.25+64.70%
- Strong buy 1
- Buy 17
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.81 vs $1.00
- Surprise
- -181.00%
DNTH news
All DNTH news- Dianthus Therapeutics, Inc. Reports Q3 2026 Financial Results and Highlights Clinical ProgressNasdaq
- Dianthus Therapeutics GAAP EPS of -$0.81 beats by $0.18Seeking Alpha
- Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial ResultsGlobeNewswire
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Dianthus Therapeutics to Participate in Five Investor Conferences During NovemberGlobeNewswire
- Regeneron (REGN) Q3 Earnings and Revenues Beat EstimatesNasdaqREGN, DNTH
- Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthNasdaqHALO, DNTH
- Why is Dianthus Therapeutics stock gaining today?Investing.com
Dianthus Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ERASErasca Inc. | 13.61 | -4.29% | $4.78B | vs DNTH |
| PTCTPTC Therapeutics Inc. | 56.42 | -3.27% | $4.71B | vs DNTH |
| LQDALiquidia Corporation | 54.43 | -3.88% | $4.90B | vs DNTH |
| COGTCogent Biosciences Inc. | 26.72 | -3.69% | $4.65B | vs DNTH |
| TVTXTravere Therapeutics Inc. | 47.00 | -2.69% | $4.51B | vs DNTH |
| MANEVeradermics Incorporated | 119.52 | -3.92% | $5.04B | vs DNTH |
| IONSIonis Pharmaceuticals Inc. | 26.58 | -2.35% | $4.43B | vs DNTH |
| BLTEBelite Bio Inc ADR | 127.38 | -15.65% | $5.17B | vs DNTH |
Indexes, lists and sector
Dianthus Therapeutics stock FAQ
What is Dianthus Therapeutics's stock price today?
DNTH last traded at $84.55 as of Nov 20, 4:00 PM EST, down 0.33% on the day. Prices are delayed at least 15 minutes.
Who is Dianthus Therapeutics's CEO?
Mr. Marino Garcia M.B.A. is the chief executive officer of Dianthus Therapeutics Inc., which has about 92 employees.
What is the DNTH 52-week high?
The 52-week high for DNTH is $117.88 and the 52-week low is $35.84. The stock is currently 28.3% below its high.